Ultragenyx, Mereo Report 14-Month Results From Phase 2 Portion Of Phase 2/3 Orbit Study; Treatment With Setrusumab Resulted In Sustained 67% Reduction In Annualized Fracture Rate In Osteogenesis Imperfecta Patients

Author: Benzinga Newsdesk | June 11, 2024 05:53pm

As of a May 24, 2024 data cut-off date, treatment with setrusumab (UX143) continued to significantly reduce incidence of fractures in patients with OI with at least 14 months of follow-up. Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density (BMD) at month 12 without evidence of plateau.

"All indications are that setrusumab is having the effect we hoped for, safely reducing the incidence of fractures and improving BMD in patients with OI," said Gary S. Gottesman, M.D., Professor of Pediatrics and Medicine, Washington University School of Medicine.

Posted In: MREO RARE